EP0730581B1 - 3-acylaminobenzazepines - Google Patents
3-acylaminobenzazepines Download PDFInfo
- Publication number
- EP0730581B1 EP0730581B1 EP95901954A EP95901954A EP0730581B1 EP 0730581 B1 EP0730581 B1 EP 0730581B1 EP 95901954 A EP95901954 A EP 95901954A EP 95901954 A EP95901954 A EP 95901954A EP 0730581 B1 EP0730581 B1 EP 0730581B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mmol
- methyl
- reaction
- mmole
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 *C(C1=CCCC=C1*(C1O)I)=CC1NC(CCc(ccc(Cl)c1)c1Cl)=O Chemical compound *C(C1=CCCC=C1*(C1O)I)=CC1NC(CCc(ccc(Cl)c1)c1Cl)=O 0.000 description 1
- FUUQAONHNPJPDN-UHFFFAOYSA-N CC(C)(C)OC(NC(C/C(/c1ccccc1N1)=[O]\C)C1=S)=O Chemical compound CC(C)(C)OC(NC(C/C(/c1ccccc1N1)=[O]\C)C1=S)=O FUUQAONHNPJPDN-UHFFFAOYSA-N 0.000 description 1
- PWRZGUSUUZCMEQ-UHFFFAOYSA-N CC(C)(C)OC(NC(CC(c1ccccc1N1)=O)C1=O)=O Chemical compound CC(C)(C)OC(NC(CC(c1ccccc1N1)=O)C1=O)=O PWRZGUSUUZCMEQ-UHFFFAOYSA-N 0.000 description 1
- AMVOFAQBJBHXOF-FVRDMJKUSA-N C[C@@H](C1)N=C(C(C2)NC(CCc(c(Cl)c3)ccc3Cl)=O)N1c1ccccc1C2=O Chemical compound C[C@@H](C1)N=C(C(C2)NC(CCc(c(Cl)c3)ccc3Cl)=O)N1c1ccccc1C2=O AMVOFAQBJBHXOF-FVRDMJKUSA-N 0.000 description 1
- HLNPVFSCAMKIOD-UHFFFAOYSA-N OC(CCc(ccc(Cl)c1)c1Cl)=O Chemical compound OC(CCc(ccc(Cl)c1)c1Cl)=O HLNPVFSCAMKIOD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- Arrthythrmias often occur as complications to cardiac diseases such as myocardial infarction and heart failure. In a serious case, arrhythmias give rise to a ventricular fibrillation and can cause sudden death.
- antiarrythmic agents are now available on the market, those having both satisfactory effects and high safety, have not been obtained.
- antiarrythmic agents of Class I according to the classification of Vaughan-Williams which cause a selective inhibition of the maximum velocity of the upstroke of the action potential (Vmax) are inadequate for preventing ventricular fibrillation.
- Vmax maximum velocity of the upstroke of the action potential
- they have problems regarding safety, namely, they cause a depression of the myocardial contractility and have a tendency to induce arrythmias due to an inhibition of the impulse conduction.
- Beta-adrenoceptor blockers and calcium antagonists which belong to Class II and IV respectively, have a defect that their effects are either limited to a certain type of arrhythmia or are contraindicated because of their cardiac depressant properties in certain patients with cardiovascular disease. Their safety, however, is higher than that of the antiarrhythmic agents of Class I.
- Antiarrythmic agents of Class III are drugs which cause a seiective prolongation of the duration of the action potential without a significant depression of the Vmax. Drugs in this class are limited. Examples such as sotalol and amiodarone have been shown to possess Class III properties. Sotalol also possesses Class II effects which may cause cardiac depression and be contraindicated in certain susceptible patients. Also, amiodarone is severely limited by side effects. Drugs of this class are expected to be effective in preventing ventricular fibrillations. Pure Class III agents, by definition, are not considered to cause myocardial depression or an induction of arrhythmias due to the inhibition of the action potential conduction as seen with Class I antiarrhythmic agents.
- EP-A-703,222 and US 4,692,522 disclose, respectively, 3-aminoazepines and benzofused lactams as cholecystokinin antagonists.
- This invention is concerned with novel compounds represented by the structural formulae: where R, R', R" and R'' have the meanings indicated hereinafter; or pharmaceutically acceptable salts, hydrates and crystal forms thereof, which are useful as antiarrhythmic agents.
- the invention is also concerned with pharmaceutical formulations comprising one of the novel compounds as an active ingredient.
- the invention is also concerned with the use of one of the novel compounds or formulation thereof for the manufacture of a medicament to prevent or treat arrythmia.
- the pharmaceutically acceptable salts, crystal forms and hydrates of the compounds of the invention include the conventional non-toxic salts or the quarternary ammonium salts of the compounds of the invention formed, e.g., from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glucolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of the invention which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are preparad by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
- novel compounds of this invention is that in which the 2,3,4,5-tetrahydrobenzo[b]azepin is utilized.
- a second embodiment of the novel compounds of this invention is that wherein the 2,3-dihydrobenzo[b]azepin is utilized.
- a third embodiment of the novel compounds of this invention is that wherein an imidazoline ring is appended at the 1,2 position of the benzazepine.
- novel compounds of the present invention have the pharmacological properties required for antiarrhythmic agents of Class III, namely the prolongation of the myocardial action potential in vitro, without a significant depression of the Vmax, and the prolongation of QTc-interval in anesthetized dogs.
- the compounds of the present invention are especially useful to control reentrant antiarrhythmias and prevent sudden death due to the ventricular fibrillation. These compounds are also effective in treating and preventing impaired cardiac pump functions.
- one of the compounds or pharmaceutically acceptable salts thereof is administered in an amount ranging from about 0.0001 to about 20 mg per kg or body weight per day, preferably from about 0.001 to about 10 mg per kg of body weight per day in a single dose or in 2 to 4 divided doses.
- These compounds can be administered as the sole active ingredient or in combination with other antiarrhythmic agents or other cardiovascular agents.
- These compounds, or pharmaceutically acceptable salts thereof, in the descibed dosages are administered orally, intraperitoneally, subcutaneously, intramuscularly, transdermally, sublingually or intravenously. They are preferably administered intravenously or orally, for example in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum, or the like prepared by art recognized procedures.
- the amount of active compound in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained.
- the activity of the compounds described herein as antiarrhythmic agents is measured by their ability to block the IKs and IKr as determined by the following test protocol.
- Outward potassium currents are measured in single guinea pig ventricular myocytes using a whole-cell voltage clamp technique described in detail elsewhere (Sanguinetti and Jurkiewicz, 1990, two components of cardiac delayed rectifier K+ current: differential sensitivity to block by Class III antiarrhythmic agents. J. Gen Physiol. 96 :195-215).
- Myocytes are isolated by enzymatic (collagenase and protease) digestion of Langandorf perfused hearts. Single cells are then voltage clamped using 1 mm square-bore pipettes filled with 0.5 M Kgluconate, 25 mM KCl, 5 mM K(2)ATP. Cells are bathed in a solution containing, in mN: 132 NaCl; 4KCl, 1.2 MgCl 2 , 10 HEPES, 10 glucose: pH 7.2, temp. 35°C.
- Test depolarizations are applied as voltage ramps from -85 to -50 mV, and as steps to -10 mV (0.5 s) and +50 mV (1.0 s).
- I[KI] is measured as peak outward current during the voltage ramp.
- I[Kr] is measured as tail currents upon repolarization from -10 mV to -50 mV.
- I[Ks] is measured as time-dependent current during the pulse to +50 mV. Currents are measured during control, then after exposure to drug at two differenct concentrations.
- the compounds described herein have an IC 50 of less then 10,000 nM as IKs and/or IKr blockers.
- Step A N-(2,5-dioxo-3,4-dihydro-1H-benzo[b]azepin-3-yl)-3- (2,4 dichlorophenyl)-propionamide
- Step B N-(1-methyl-2,5-dioxo-3,4-dihydro-1H-benzo[b]azepin-3- yl)-3-(2.4-dichlorophenyl)-propionamide
- Step A Preparation of 1-methyl-3-tertbutyloxycarbonylamino- 2,3,4,5-tetrahydro-2,5-dioxobenzazepine
- Step B Preparation of 5-phenyl 3-(tert-butoxycarbonylamino)-1- methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepine
- the material thus obtained was dissolved in dimethoxyethane (70 mL), and treated with 7.5 mL of a 2N solution of sodiumcarbonate, phenyl boronic acid (932 mg, 7.6 mmole), palladium tetrakistriphenylphophine (329 mg, 0.28 mmole), and LiCl (966 mg, 22.7 mmole).
- the reaction mixture was then heated to reflux for 2.5 hr. the reaction was cooled to room temperature and then poured into saturated sodium bicarbonate (800 mL).
- the aqueous mixture was extracted with ethyl acetate (3X200 mL).
- the combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure.
- Step C Preparation of 5-phenyl-3-amino)-1-methyl-2-oxo-2,3- dihydro-1H-benzo[b]azepine hydrochloride
- Step D Preparation of N-(2,3-Dihydro-2-oxo-1-methyl-5-phenyl- 1H-lbenzazepin-3-yl)-3-cyclohexyl-propanamide
- Epimerization of the cis isomer to the trans isomer was accomplished by adding potassium t-butoxide (75 mg, 0.67 mmol) to a solution of cis-N-(2,3,4,5-tetrahydro-2-oxo-1-methyl-5-phenyl-1H-benzazepin-3-yl)-3-cyclohexylpropanamide (90 mg, 0.22 mmol) in tetrahydrofuran (10 ml) and heating to 50°C for 18 hours. The mixture was diluted with ethyl acetate (50 ml) and saturated aqueous sodium hydrogen carbonate (100 ml).
- Step A 3-[3-(tert-butoxycarbonylamino)-5-cyano-1-methyl-2- oxo-2,3-dihydro-1H-benzo[b]azepin
- Step B Preparation of N-(5-Cyano-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-3-yl)-3-(2,4-dichloro-phenyl)- propionamide
- Step A
- Step B
- Step A
- Step B
- Step A
- Step B
- Step A
- Step B
- Step A
- Step B
- Step A 3-tertbutyloxyearbonylamino-2,3,4,5-tetrahydro-2-thio-5- oxo-benzo[b]azepine
- Step B 1,2-dihydro-2-methyl-4-(tertbutyloxycarbonylamino)-4H- imidazo [1,2-a]-6-oxobenzazepine
- Step C 2-(S)-N-(1,2-dihydro-2-methyl-4H-imidazo[1,2-a]-6- oxobenzazepin-4-yl)-3-(2,4-dichlorophenylopropanamide
- the reaction was stirred at room temperature for 30 minutes and then poured into saturated sodium bicarbonate (400 mL). The aqueous mixture was extracted with ethyl acetate (3 X 100 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered and concentrated at reduced pressure. The residue was then chromatographed with 1.5% methanol/chloroform to give the product (590 mg) as a mixture of isomers. The isomers were separated by chromatography on silica eluting with ethyl acetate.
- Isomer A crystallized from ethylacetate/Hexane. Isomer B was converted into the hydrochloride salt and freeze dried. Isomer A: mp 134-136°C, Anal. Calcd for C 22 H 21 C1 2 N 3 O 2 C, 62.25; H, 5.36; N, 9.39. Found C, 62.04; H, 5.51; N, 9.06. Isomer B: Anal Calcd for C 22 H 21 Cl 2 N 3 O 2 •HCl C, 53.60; H, 5.09; N, 8.53. Found C, 53.56; H, 4.98; N, 8.19.
- Step A 3-benzyloxyoxycarbonylamino-2,3,4,5-tetrahydro-2- thiobenzo[b]azepine
- Step B 1,2-dihydro-2-methyl-4-(benzyloxycarbonylamino)-4H-imidazo[1,2-a]-benzazepine
- Step C 2-(S)-N-(1,2,5,6-tetrahydro-2-methyl-4H-imidazo[1,2-a]benzazepin-4-yl)-3-(2,4-dichlorophenyimpropimamide.
- a solution of 1,2-dihydro-2-methyl-4-(benzyloxycarbonylamino)-4H-imidazo[1,2-a]-benzazepine (458 mg, 1.31 mmole) in methylene chloride (4 mL) was treated with excess HBr in acetic acid (5 mL of 30% solution) until all of the starting material had been consumed.
- the reaction was diluted with ether (100 mL) and the solvent decanted.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
- Arrthythrmias often occur as complications to cardiac diseases such as myocardial infarction and heart failure. In a serious case, arrhythmias give rise to a ventricular fibrillation and can cause sudden death.
- Though various antiarrythmic agents are now available on the market, those having both satisfactory effects and high safety, have not been obtained. For example, antiarrythmic agents of Class I according to the classification of Vaughan-Williams which cause a selective inhibition of the maximum velocity of the upstroke of the action potential (Vmax) are inadequate for preventing ventricular fibrillation. In addition, they have problems regarding safety, namely, they cause a depression of the myocardial contractility and have a tendency to induce arrythmias due to an inhibition of the impulse conduction. Beta-adrenoceptor blockers and calcium antagonists which belong to Class II and IV respectively, have a defect that their effects are either limited to a certain type of arrhythmia or are contraindicated because of their cardiac depressant properties in certain patients with cardiovascular disease. Their safety, however, is higher than that of the antiarrhythmic agents of Class I.
- Antiarrythmic agents of Class III are drugs which cause a seiective prolongation of the duration of the action potential without a significant depression of the Vmax. Drugs in this class are limited. Examples such as sotalol and amiodarone have been shown to possess Class III properties. Sotalol also possesses Class II effects which may cause cardiac depression and be contraindicated in certain susceptible patients. Also, amiodarone is severely limited by side effects. Drugs of this class are expected to be effective in preventing ventricular fibrillations. Pure Class III agents, by definition, are not considered to cause myocardial depression or an induction of arrhythmias due to the inhibition of the action potential conduction as seen with Class I antiarrhythmic agents.
- EP-A-703,222 and US 4,692,522 disclose, respectively, 3-aminoazepines and benzofused lactams as cholecystokinin antagonists.
- This invention is concerned with novel compounds represented by the structural formulae: where R, R', R" and R''' have the meanings indicated hereinafter;
or pharmaceutically acceptable salts, hydrates and crystal forms thereof, which are useful as antiarrhythmic agents. The invention is also concerned with pharmaceutical formulations comprising one of the novel compounds as an active ingredient. - The invention is also concerned with the use of one of the novel compounds or formulation thereof for the manufacture of a medicament to prevent or treat arrythmia.
- The pharmaceutically acceptable salts, crystal forms and hydrates of the compounds of the invention include the conventional non-toxic salts or the quarternary ammonium salts of the compounds of the invention formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glucolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
- The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of the invention which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are preparad by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
- One embodiment of the novel compounds of this invention is that in which the 2,3,4,5-tetrahydrobenzo[b]azepin is utilized.
-
- A second embodiment of the novel compounds of this invention is that wherein the 2,3-dihydrobenzo[b]azepin is utilized.
-
-
-
- The novel compounds of the present invention, have the pharmacological properties required for antiarrhythmic agents of Class III, namely the prolongation of the myocardial action potential in vitro, without a significant depression of the Vmax, and the prolongation of QTc-interval in anesthetized dogs.
- These compounds are effective in treating and preventing all types of arrhythmias including ventricular and atrial (supraventricular) arrhythmias. The compounds of the present invention are especially useful to control reentrant antiarrhythmias and prevent sudden death due to the ventricular fibrillation. These compounds are also effective in treating and preventing impaired cardiac pump functions.
- In the novel method of this invention of treating arrhythmia, one of the compounds or pharmaceutically acceptable salts thereof, is administered in an amount ranging from about 0.0001 to about 20 mg per kg or body weight per day, preferably from about 0.001 to about 10 mg per kg of body weight per day in a single dose or in 2 to 4 divided doses.
- These compounds can be administered as the sole active ingredient or in combination with other antiarrhythmic agents or other cardiovascular agents.
- These compounds, or pharmaceutically acceptable salts thereof, in the descibed dosages, are administered orally, intraperitoneally, subcutaneously, intramuscularly, transdermally, sublingually or intravenously. They are preferably administered intravenously or orally, for example in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum, or the like prepared by art recognized procedures. The amount of active compound in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained.
- The activity of the compounds described herein as antiarrhythmic agents is measured by their ability to block the IKs and IKr as determined by the following test protocol.
- Outward potassium currents are measured in single guinea pig ventricular myocytes using a whole-cell voltage clamp technique described in detail elsewhere (Sanguinetti and Jurkiewicz, 1990, two components of cardiac delayed rectifier K+ current: differential sensitivity to block by Class III antiarrhythmic agents. J. Gen Physiol. 96:195-215). Myocytes are isolated by enzymatic (collagenase and protease) digestion of Langandorf perfused hearts. Single cells are then voltage clamped using 1 mm square-bore pipettes filled with 0.5 M Kgluconate, 25 mM KCl, 5 mM K(2)ATP. Cells are bathed in a solution containing, in mN: 132 NaCl; 4KCl, 1.2 MgCl2, 10 HEPES, 10 glucose: pH 7.2, temp. 35°C.
- Each cell is maintained at a holding potential of -50 mV. Test depolarizations are applied as voltage ramps from -85 to -50 mV, and as steps to -10 mV (0.5 s) and +50 mV (1.0 s). I[KI] is measured as peak outward current during the voltage ramp. I[Kr] is measured as tail currents upon repolarization from -10 mV to -50 mV. I[Ks] is measured as time-dependent current during the pulse to +50 mV. Currents are measured during control, then after exposure to drug at two differenct concentrations.
- Employing this test the compounds described herein have an IC50 of less then 10,000 nM as IKs and/or IKr blockers.
-
- N-(1-methyl-2,5-dioxo-3,4-dihydro-1H-benzo[b]azepin-3-yl)-3-(2,4- dichlorophenyl)-propionamide
- A 100 mL round bottom flask was charged with 3-amino-3,4-dihydro-1H-benzo[b]azepin-2,5-dione (4 g, 17.6 mmole), EDC (3.38 g, 17.6 mmole), HOBT (2.38 g, 17.6 mmole), 2,4-dichlorophenyl propionic acid (3.86 g, 17.6 mmole), Dimethylformamide (100 mL), and triethylamine (1.78 g, 17.6 mmole). The reaction mixture was stirred at room temperature for 1 hr. and then poured into saturated sodium bicarbonate (500 mL). The aqueous mixture was extracted with ethyl acetate (3X200 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure. The resulting solid was swished with a minimum of hot chloroform and filtered to give the product, 5.8 g (84%) mp 234-236°C.
- A 100 mL round bottom flask was charged with N-(2,5-dioxo-3,4-dihydro-1H-benzo[b]azepin-3-yl)-3-(2,4-dichlorophenyl)-propionamide (2.5 g, 6.38 mmole), potassium carbonate (1.76 g, 12.7 mmole), DMF (20 mL), and iodomethane (3.55 g, 25 mmole). The reaction mixture was stirred at room temperature for 5 hr. and then poured into saturated sodium bicarbonate (500 mL). The aqueous mixture was extracted with ethyl acetate (3X200 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure. The resulting solid was swished with a minimum of warm ether and filtered to give 2.1 g (81%) of the product. mp 182-184°C.
Anal. Clacd for C20H18N2O3Cl2 C, 59.27; H, 4.48; N, 6.91. Found C, 59.27; H, 4.47; N, 7.11. -
- To a stirred suspension of 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-propionamide (3.7 mmol,1.5 g) in 15 ml EtOH and 5 ml THF was added NaBH4 (3.7 mmol, 0.14 g). This was stirred at rt for lh. The reaction was then diluted with 200 ml EtOAc and extracted with 2x100 ml 1N HCl. The organic layter was dried with brine and evaporated under vacuum to 1.4 g of a white powder. The solid was carried on without further purification. To a stirred suspension of the above alcohol in 4 ml CH2Cl2 was added acetic anhydride (0.73 mmol, 75 mg, 0.07 ml), triethyl amine (0.73 mmol, 74 mg, 0.10 ml), 4-dimethylaminopyridine (0.098 mmol,11.9 mg) and the reaction was stirred at rt. The reaction mixture was then diluted with 25 ml CH2C12 and extracted with 25 ml H2O, 25 ml saturated NaHCO3. The organic phase was dried with brine and evaporated to a colorless oil. The resulting oil was chromatographed over silica, eluting with 20% to 50% EtOAc:Hex. The pure fractions were collected, evaporated under vacuum, taken up in CH2C12 and allowed to evaporate to dryness overnight, resulting in 110 mg of a white solid. mp 142-144°C:
1H NMR (CDCl3, 300 MHz) δ 7.43-7.11 (m, 7H), 6.57 (d, J=6.3Hz, 1H), 5.94 (dd, J=11.2 and 7.8Hz, 1H), 4.35 (m, 1H), 3.41 (s, 3H), 2.97 (t, J=7.3Hz, 2H) 2.67 (m, 1H), 2.48 (t, J=7.3Hz, 2H), 2.24 (m, 1H), 2.19 (s, 3H).Anal. Calcd for C22H22N2O4Cl2•0.10 H20•0.05 CH2Cl2 C, 58.16; H, 4.94; N, 6.15. Found C, 58.18; H, 4.77; N, 6.10. -
- To a stirred suspension of 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-propionamide (3.7 mmol, 1.5 g) in 15 ml EtOH and 5 ml THF was added NaBH4 (3.7 mmol, 0.14 g). This was stirred at rt for 1h. The reaction was then diluted with 200 ml EtOAc and extracted wtih 2x100 ml 1N HCL The organic layer was dried with brine and evaporated under vacuum to 1.4 g of a white powder. The solid was carried on without further purification. To a stirred suspension of the above alcohol in 4 ml CH2Cl2 was added benzoyl chloride (1.1 mmol, 0.15 g, 0.13 ml), 4-dimethylaminopyridine (0.49 mmol, 59.9 mg) and the reaction was stirred at rt. The reaction mixture was then diluted with 25 ml CH2Cl2 and extracted with 25 ml H2O. The organic phase was dried with brine and evaporated to a colorless oil. The resulting oil was chromatographed over silica, eluting with 20%o EtOAc:Hex. The pure fractions were collected, evaporated under vacuum, crystallized from EtOAc:Hex to give 169 mg of a white solid. mp 171-173°C 1H NMR (CDCl3, 300 MHz) δ 8.15 (d, J=7.1Hz, 2H), 7.67-7.10 (m, 10H), 6.62 (d, J=6.6Hz, 1H), 6.21 (dd, J=7.8 and 11.2), 4.48-4.39 (m, 1H), 3.46 (s, 3H), 2.98 (t, J=7.3Hz, 2H), 2.89 (m, 1H), 2.50 (t, J=7.3Hz, 2H), 2.41-2.31 (m, 1H).
Anal. Calcd for C27H24N2O4C12•0.30H2O C, 62.75; H, 4.80; N, 5.42. Found C, 62.78; H, 4.79; N, 5.32. -
- A 100 mL round bottom flask was charged with N-(2,5-dioxo-3,4-dihydro-1H-benzo[b]azepin-3-yl)-3-(2,4-dichlorophenyl)-propionamide (1.95 g, 5 mmole), potassium carbonate (1.38 g, 10 mmole), DMF (20 mL), and 2-iodopropane (3.5 g, 20 mmole). The reaction mixture was stirred at room temperature for 24 hr. and then poured into saturated sodium bicarbonate (200 mL). The aqueous mixture was extracted with ethyl acetate (3X100 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure. The residue was chromatographed on silica gel eluting with 40% ethylacetate/hexane to give 1.4 g of product. (64%) mp 107-109°C
Anal. Clacd for C22H22N2O3Cl2 C, 60.98; H, 5.12; N, 6.46. Found C, 61.18; H, 5.13; N, 7.11. -
- To a stirred solution of N-(1-(2-propyl)-2,5-idioxobenzazepin-3-yl)-3-(2,4-dichlorophenyl) propanamide (0.50 g, 1.15 mmol) in ethanol (25 ml) was added sodium borohydride (87 mg, 2.31 mmol). After 15 minutes, the mixture was diluted with ethyl acetate (100 ml) and saturated aqueous sodium hydrogen carbonate (200 ml). The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (2x100 ml). The organic layers were combined and condensed in vacuo. The resulting oil was crystallized from ethyl acetate/hexane, yielding a white solid (435 mg, 87%). This solid was then dissolved in methylene chloride (30 ml). To this was added triethylamine (167 µl, 1.20 mmol) and then methanesulfonylchloride (93 µl, 1.20 mmol). After one hour, the mixture was diluted with ethyl acetate (100 ml) and saturated aqueous sodium hydrogen carbonate (200 ml). The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (2x100 ml). The organic layers were combined and condensed in vacuo. A portion of the resulting foam (100 mg, 0.20 mmol) was then dissolved in toluene (5 ml) and to this was added catalytic p-toluenesulfonic acid (30 mg), and the mixture was heated to 100°C for one and one half hours. The mixture was then cooled to room temperature, diluted with ethyl acetate (75 ml) and saturated aqueous sodium hydrogen carbonate (100 ml). The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (2x50 ml). The organic layers were combined and condensed in vacuo. The resulting oil was chromatographed over silica with 1:3 ethyl acetate/hexane, yielding a white solid (35 mg, 43%). m.p. 142-143°C. 1H NMR δ 7.38-7.05 (m, 8H), 6.68 (dd, J=2.2, 9.8Hz, 1H), 5.70 (dd, J=6.4, 9.8Hz, 1H), 4.50-4.40 (m, 2H), 3.06 (t, J=7.4Hz, 2H), 2.60 (t, J=7.8Hz, 2H), 2.60 (t, J=7.4Hz, 2H), 1.45 (d, J=6.8Hz, 3H), 1.16 (d, J=6.8Hz, 3H).
Anal. Calcd. for C22H22N2O2Cl2 C, 63.32; H, 5.31; N, 6.71. Found C, 63.16; H, 5.24; N, 6.84%. -
- A solution of 3-tertbutyloxycarbonylamino-2,3,4,5-tetrahydro-2,5-dioxobenzo[b]azepine (5 g, 17.2 mmole) in DMF (50 mL) was treated with potassium carbonate (4.76 g, 34.4 mmole) and methyl iodide (4.88 g, 34.4 mmole). The reaction was stirred at ambient temperature for 4 hours. The mixture was diluted with ethyl acetate (300 ml) and saturated aqueous sodium hydrogen carbonate (500 ml). The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (2x300 ml). The organic layers were combined, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The resulting solid was swished with warm ethyl ether (200 mL) and collected by filtration to give 4.1 g of the product. mp 205-206°C.
1H NMR (300 MHz, CDCl3) δ 7.60-7.50 (m, 2H), 7.35-7.20 (m, 2H), 5.77 (m, 1H), 4.9 (m, 1H), 3.41 (s, 3H), 3.33 (dd, J=3.5, 12.5 Hz), 3.33 (dd, J=12.5, 18 Hz), 1.43 (s, 9H). - A solution of 1-methyl-3-tertbutyloxycarbonylamino-2,3,4,5-tetrahydro-2,5-dioxobenzazepine (3 g, 9.8 mmole) in THF (100 mL) at 0°C was treated with a solution of LDA in THF (7 mL of 2N soln). The reaction was stirred at 0°C for five minutes and a solution of N-phenyltriflimide (3.92 g, 11 mmole) in THF (10 mL) was added. The reaction was stirred at 0°C for 1.5 hr and then poured into saturated sodium bicarbonate (800 mL). The aqueous mixture was extracted with ethyl acetate (3X200 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure. The residue was chromatographed on silica gel eluting with 25% ether/hexanes then rechromatographed using 2%-10% ethylacetate/chloroform as eluent to give 2.4 g of product. (64%).
- The material thus obtained was dissolved in dimethoxyethane (70 mL), and treated with 7.5 mL of a 2N solution of sodiumcarbonate, phenyl boronic acid (932 mg, 7.6 mmole), palladium tetrakistriphenylphophine (329 mg, 0.28 mmole), and LiCl (966 mg, 22.7 mmole). The reaction mixture was then heated to reflux for 2.5 hr. the reaction was cooled to room temperature and then poured into saturated sodium bicarbonate (800 mL). The aqueous mixture was extracted with ethyl acetate (3X200 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure. The residue was chromatographed on silica gel eluting with 30% ethyl acetate/hexanes to give 1.68 g of the product. (63%). 1H NMR (300 MHz CDCl3) δ 7.5-7.10 (m, 9H), 6.11 (d, J=3.1Hz, 1H), 5.9 (d, J=5.6 Hz, 1H), 4.45 (m, 1H), 3.46 (s, 3H), 1.44 (s, 9H).
- A solution of 5-phenyl 3-(tert-butoxycarbonylamino)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepine prepared as described above 1.8 g (4.9 mmole) in ethyl acetate was treated with excess gaseous HCl until all the starting material was consumed. The reaction was then concentrated at reduced pressure and the solid collected to give the product 1.4 g (95%) mp 194-200°C.
- To a stirred solution of 3-amino-5-phenyl-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin hydrochloride salt (0.50 g, 1.66 mmol) in N,N-dimethylformamide (25 ml) was added 3-cyclohexylpropionic acid (311 mg, 2.0 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (381 mg, 2.0 mmol), 1-hydroxybenzotriazole hydrate (269 mg, 2.0 mmol), and triethylamine (277 ml, 2.0 mmol). After three hours, the mixture was diluted the ethyl acetate (100 ml) and saturated aqueous sodium hydrogen carbonate (200 ml). The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (2x100 ml). The organic layers were combined and condensed in vacuo. The resulting oil was chromatographed over silica with 3:7 ethyl acetate/hexane. Upon removal of eluent in vacuo, a white solid was recovered (0.540 mg, 81%). m.p. 219-220°C. 1H NMR δ 7.45-7.12 (m, 9H), 7.07 (d, J=6.1 Hz, 1H), 5.91 (d J=5.4 Hz, 1H), 4.62 (t, J=5.8 Hz, 1H), 3.48 (s, 3H), 2.33 (t, J=6.3 Hz, 2H), 1.80-1.52 (m, 7H), 1.38-1.10 (m, 4H), 1.00-0.82 (m, 2H).
Anal. Calcd. for C26H30N2O2•0.75 H2O C, 76.38; H, 7.57, N, 6.85. Found C, 76.29; H, 7.36, N, 6.95%. -
- A solution of N-(2,3-Dihydro-2-oxo-1-methyl-5-phenyl-1H-1-benzazepin-3-yl)-3-cyclohexyl-propanamide (250 mg) in methanol (20 ml) was added to a suspension of 10% palladium on carbon (100 mg) in methanol (20 ml). This mixture was subjected to 50 psi of hydrogen on a Parr shaker for two hours. The mixture was then filtered over celite and concentrated at reduced pressure. The resulting foam was crystallized from a mixture of ethyl acetate and hexane, yielding a white solid (200 mg, 80%), which is a cis, racemic mixture. m.p. 156-158°C. 1H NMR δ 7.45-7.02 (m, 9H), 6.72 (s, 1H), 4.61-4.49 (m, 1H), 4.20 (d, J=7.5 Hz, 1H), 3.23-3.10 (m, 1H), 2.62-2.51 (m, 1H), 2.21 (t, J=8.3 Hz, 2H), 1.75-1.44 (m, 8H), 1.30-1.05 (m, 3H), 0.96-0.78 (m, 2H).
Anal. Calcd. for C26H32N2O2 C, 77.19; H, 7.97; N, 6.92. Found C, 77.19; H, 7.93; N, 7.02%. -
- Epimerization of the cis isomer to the trans isomer was accomplished by adding potassium t-butoxide (75 mg, 0.67 mmol) to a solution of cis-N-(2,3,4,5-tetrahydro-2-oxo-1-methyl-5-phenyl-1H-benzazepin-3-yl)-3-cyclohexylpropanamide (90 mg, 0.22 mmol) in tetrahydrofuran (10 ml) and heating to 50°C for 18 hours. The mixture was diluted with ethyl acetate (50 ml) and saturated aqueous sodium hydrogen carbonate (100 ml). The organic layer was separated and the aqueous layer was extracted again with ethyl acetate (2x40 ml). The organic layers were combined and concentrated at reduced pressure. The resulting mixture of isomers was crystallized from a mixture of ethyl acetate and hexane, from which was obtained the desired trans isomer (35 mg, 39%). m.p. 185-186°C. 1H NMR δ 7.40-7.09 (m, 8H), 6.74 (d, J=8.4 Hz, 1H), 6.61 (d, J=6.6 Hz, 1H), 4.60-4.50 (m, 1H), 4.32-4.22 (m, 1H), 3.51 (s, 3H), 3.33-3.10 (m, 1H), 2.21 (t, J=7.8 Hz, 2H), 2.15-2.02 (m, 1H), 1.76-1.44 (m, 5H), 1.30-1.15 (m, 4H), 0.96-0.80 (m, 2H).
Anal. Calcd. for C26H32N202•H2O C, 76.01; H, 8.02; N, 6.82. Found C, 76.00; H, 7.75; N, 6.91 %. -
- To a stirring solution of 3-amino-5-phenyl-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin hydrochloride salt (0.66 mmol, 0.2 g) in 5 ml DMF was added EDC: (1.3 mmol, 0.25 g), HOBT (1.3 mmol, 0.18 g), 2,5-dichlorophenyl-propionic acid (1.3 mmol,0.29 g), triethylamine (1.3 mmol, 0.13 g) and the reaction was stirred at rt for 1h. The reaction was then diluted with 100 ml saturated NaHCO3 and extracted with 2 x 50 ml EtOAc. The combined organic layers were dried with Na2SO4 and evaporated under vacuum. The residue was chromatographed over silica, eluting with 20% to 50% EtOAc:Hex. The pure fractions were collected, evaporated under vacuum and crystallized from Et2O to give 0.22 g of a fluffy white solid. mp 102-104°C: 1H NMR (300 MHz, CDC13) δ 7.44-7.14 (m, 12H), 7.05 (d, J=6.4Hz, 1H), 5.79 (d, J=5.1Hz, 1H),4.58 (t, J=5.6Hz, 1H), 3.47 (s, 3H),3.09 (t, J=7.6Hz, H), 2.63 (t, J=7.6Hz, 2H).
Anal. Calcd. for C26H22N2O2C12•0.50 H2O C, 65.93; H, 4.89; N, 5.91. Found C, 65.85; H, 4.77; N, 5.78. -
- To a stirred solution of the trifluoromethane sulfonic acid 3-[3-(tert-butoxycarbonylamino-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl ester (0.2 g, 0.46 mmol) in anhydrous DMF was added the Pd[PPh3]4 (0.069 mmol, 79.7 mg) and Zn(CN)2 (0.92 mmol, 0.11 g). The reaction was heated to 80°C for 0.5h, cooled to rt. and diluted with 100 ml H2O. This was extracted with 2x50 ml EtOAc. The combined organic layers were dried with brine and Na2SO4. The extracts were evaporated under vacuum to an orange oil which became a solid on standing. This was chromatographed over silica eluting with 50% EtOAc:Hex, giving 109 mg of a pale yellow solid, 80%. 1H NMR (300 MHz, CDC13) δ 7.75-7.26 (m,4H), 6.67 (d, J=5.1Hz, 1H), 6.12 (d, J=6.4Hz, 1H), 4.45 (t, J=5.8Hz, 1H), 3.44 (s,3H), 1.44 (s, 9H).
- To a stirring solution of the 3-[3-(tert-butoxycar-bonylamino)]-5-cyano-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin (0.35 mmol, 0.11 g) in 5 ml EtOAc was bubbled HCl gas for 0.5h, resulting in precipatate formation. The reaction mixture was evaporated under vacuum to 85.7 mg of a yellow solid which was carried on without further purification.
- To a stirring solution of 3-amino-5-cyano-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin hydrochloride salt (0.34 mmol, 85 mg) under an argon atmosphere in 2 ml DMF was added the 2,4-(dichlorophenyl)-propionic acid (0.51 mmol, 0.11 g), EDC (0.51 mmol, 97.9 mg), HOBT (0.51 mmol, 68.9 mg), and triethyl amine (0.34 mmol, 0.05 ml). This was stirred at rt for 1h. The reaction was diluted with 50 ml saturated sodium bicarbonate and extracted with 2x20 ml EtOAc. The combined organics were washed with 10% KHSO4, dried with brine and Na2SO4, and evaporated under vacuum. The resulting lavender solid was chromatographed over silica, eluting with 20% to 70% EtOAc:Hex to give 72 mg of a white solid. mp=151-154°C. 1H NMR (300 MHz, CDC13) δ 7.71 (d, J=7.8Hz, 1H), 7.56-7.15 (m, 7H), 7.02 (d, J=4.7Hz, 1H), 6.49 (d, J=5.4Hz, 1H), 4.57 (t, J=5.4Hz, 1H), 3.45 (s, 3H), 3.05 (d, J=7.6 Hz, 2H), 2.62 (d, J=7.8Hz, 2H).
Anal. Calcd. for C21H17C12N3O2•0.05 hex.1.10 H2O C, 60.86; H, 4.29; N, 10.00. Found C, 60.89; H, 4.20; N, 9.96. -
- To a stirring solution of 3-(2,4 Dichloro-phenyl)-N-(1-(2-propyl)-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-propionamide (0.81 mmol, 0.35 g) in THF (5 ml) cooled in an ice bath was added LDA (1.1 mmol, 0.56 ml of a 2M solution) dropwise and stirred for 5 mins. To this solution was added N-phenyltrifluoro-methylsulfonimide (1.1 mmol, 0.39 g) and the reaction stirred in ice for 1h. The reation was diluted with 50 ml H2O and extracted with 2 x 25 ml EtOAc. The combined organics were dried with biine and Na2SO4. This was evaporated to a yellow oil which was carried on without further purification.
- The above oil was taken up in 5 ml DMF. To this solution was added Pd[PPh3]4 (0.26 mmol, 0.31 g), Zn(CN)2 (1.1 mmol, 0.12 g) and the reaction was heated to 80°C for 0.5h. The reaction was cooled to rt, diluted with saturated Na2C03, and extracted with 2x50 ml EtOAc. The combined 5 organics were dried with brine, Na2SO4 and evaporated under vacuum. The residue was chromatographed over silica, eluting with 20% to 70% EtOAc:Hex. The pure fractions were collected, evaporated under vacuum, and crystallized from ethyl ether to give 100 mg of a pale yellow solid. mp 103-106°C 1H NMR (300 MHz, CDC13) δ 7.72-7.02 (m, 8H), 6.50 (d, J=5.3Hz, 1H), 4.53 (h, J=6.8Hz, 1H), 3.04 (t, J=7.3Hz, 2H), 2.61 (t, J=7.3Hz, 2H), 1.47 (d, J=6.8Hz, 3H), 1.19 (d, J=6.8Hz, 3H).
Anal. Calcd. for C23H21N3O2C12•0.05 Et2O•0.30 H2O C, 61.72; H, 4.93; N, 9.31. Found C, 61.74; H, 4.74; N, 9.22. -
- To a stirring solution of 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2,5-diox-2,3,4.5-tetrahydro-1H-benzo[b]azepin-3-yl)-propionamide (7.1 mmol, 2.88 g) in 58 ml THF cooled in an ice bath was added the LDA (9.9 mmol, 5.M of a 2M heptane/THF/ethylbenzene soln) dropwise and the solution stirred for 5 min. To this was added N-phenyltrifluoromethylsulfonimide (9.9 mmol, 3.54 g) and the reaction stirred in an ice bath for 1h. The reaction was diluted with 200 ml H2O and extracted with 2x100 ml EtOAc. The combined organics were dried with brine and Na2SO4 and evaporated under vacuum to a pale yellow solid. 1H NMR (300 MHz, CDC13) δ 6 7.72-6.99 (m, 8H), 5.80 (d, J=4.9Hz, 1H), 4.44 (t, J=5.6Hz, 1H), 3.44 (s, 3H), 3.05 (t, J=7.6Hz, 2H), 2.61 (t, J=7.6Hz, 2H).
- To a stirring solution of trifluoromethane sulfonic acid 3-[3-(2,4-dichlorophenyl)-propionylamino]-1 -methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl ester (0.37 mmol, 0.2 g) in 7 ml DME was added the Na2CO3 (0.74 mmol, 0.37 ml of a 2M aqueous solution), Pd[PPh3]4 (0.037 mmol, 42.7 mg), LiCl (1.1 mmol,47.1 mg), o-methoxyphenylboronic acid (0.74 mmol, 0.11 g), and the reaction heated to reflux for 2h. After 2h o-methoxyphenylboronic acid (0.74 mmol, 0.1 1 g), and Pd[PPh3]4 (0.019 mmol, 21.4 mg) were added and heating continued for 2h. The reaction was cooled to rt, diluted with 30 ml saturated NaHCO3 and extracted with 2x20 ml EtOAc. The combined organics were washed with 10% KHSO4, dried with brine, Na2S04 and evaporated under vacuum. This residue was chromatographed over silica elutiong with 20% to 40% EtOAc:Hex. The pure fractions were collected and evaporated to a colorless oil which crystallized from Et2O to give 65 mg of a white solid. mp 203-205°C: 1H NMR (300 MHz, CDC13) δ 7.37-6.98 (m, 8H), 6.84 (d, J=7.6Hz, 1H), 5.68 (d, J=5.1 Hz, 1H), 4.63 (t, J=5.3Hz, 1H), 3.50 (s, 3H), 3.48 (s, 3H), 3.08 (t, J=7.3Hz, 2H), 2.62 (t, J=7.3Hz, 2H)
Anal. Calcd. for C27H24C12N2O3•0.25 H2O C, 64.87; H, 4.94; N, 5.60. Found C, 64.81; H, 4.78; N, 5.83. -
- To a stirring solution of 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-propionamide (7.1 mmol, 2.88 g) in 58 ml THF cooled in an ice bath was added the LDA (9.9 mmol, 5.0 ml of a 2M heptane/THF/-ethylbenzene soln) dropwise and the solution stirred for 5 min. To this was added N-phenyltrifluoromethyl-sulfonimide (9.9 mmol, 3.54 g) and the reaction stirred in an ice bath for 1h. The reaction was diluted with 200 ml H2O and extracted with 2x100 ml EtOAc. The combined organics were dried with brine and Na2SO4 and evaporated under vacuum to a pale yellow solid. 1H NMR (300 MHz, CDC13) δ 7.72-6.99 (m, 8H), 5.80 (d, J=4.9Hz, 1H), 4.44 (t, J=5.6Hz, 1H), 3.44 (s, 3H), 3.05 (t, J=7.6Hz, 2H), 2.61 (t, J=7.6Hz, 2H).
- To a stirring solution of trifluoromethane sulfonic acid 3-[3-(2,4-chlorophenyl)-propionylamino]-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl ester (0.37 mmol, 0.2 g) in 7 ml DME was added the Na2CO3 (0.74 mmol, 0.37 ml of a 2M aqueous solution), Pd[PPh3]4 (0.037 mmol, 42.7 mg), LiCl (1.11 mmol, 47.1 mg), (3-furyl)-boronic acid and the mixture heated to reflux for 2h. The reaction was cooled to rt, diluted with 50 ml saturated NaHCO3, and extracted with 2x30 ml EtOAc. The combined organics were washed with KHSO4, dried with brine, Na2SO4 and evaporated under vacuum. The residue was chromatographed over silica, eluting with 30% to 40% EtOAc:Hex. The pure fractions were collected, evaporated under vacuum, and crystallized from Et2O to give 3C) 85.0 mg of a white solid. mp 114-117°C 1H NMR (300 MHz, CDC13) δ 7.59-7.15 (m, 8H), 7.02 (d, J=4.2Hz, 1H), 6.46-6.45 (m, 1H), 5.77 (d, J=5.6Hz, 1H), 4.57 (t, J=5.9Hz, 1H), 3.44 (s, 3H), 3.07 (t, J=7.6Hz, 2H), 2.62 (t, J=7.6Hz, 2H). Anal.
Calcd for C24H21N2O3Cl2•0.20 H2O C, 62.67; H, 4.69; N, 6.09. Found C, 62.62; H, 4.49; N, 5.84. -
- To a stirring solution of 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-propionamide (7.1 mmol, 2.88 g) in 58 ml THF cooled in an ice bath was added the LDA (9.9 mmol, 5.0 ml) of a 2M heptane/THF/ etbylbenzene soln) dropwise and the solution stirred for 5 min. To this was added N-phenyltrifluoromethylsulfonimide (9.9 mmol, 3.54 g) and the reaction stirred in an ice bath for 1h. The reaction was diluted with 200 ml H2O and extracted with 2x100 ml EtOAc. The combined organics were dried with brine and Na2SO4 and evaporated under vacuum to a pale yellow solid. 1H NMR (300 MHz, CDC13) δ 7.72-6.99 (m, 8H), 5.80 (d, J=4.9Hz, 1H), 4.44 (t, J=5.6Hz, 1H), 3.44 (s, 3H), 3.05 (t, J=7.6Hz, 2H), 2.61 (t, J=7.6Hz, 2H).
- To a stirring solution of trifluoromethane sulfonic acid 3-[3-(2,4-dichlonohenyl)-propionylaminol-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl ester (0.37 mmol, 0.2 g) in 7 ml DME was added the Na2C03 (0.74 mmol, 0.37 ml of a 2M aqueous solution), Pd[PPh3]4 (0.037 mmol, 42.7 mg), LiCl (1.11 mmol,47.1 mg), (3-benzothiophene) boronic acid (1.48 mmol, 0.26 g) and the mixture heated to reflux for 2h. The reaction was cooled to rt, diluted with 100 ml H2O and extracted with 2x50 ml EtOAc. The combined organics were dried with Na2SO4 and evaporated under vacuum. This residue was chromatographed over silica, eluting with 25% EtOAc:Hex. The pure fractions were collected, evaporated under vacuum and crystallized from Et2O to give 90 mg of a beige solid. mp 179.5-181°C: 1H NMR (300 MHz,CDCl3) δ 7.90-7.86 (m, 1H), 7.44-7.07 (m, 11H), 5.91 (d, J=5.1Hz, 1H), 4.67 (t, J=5.4, 1H), 3.56 (s, 3H), 3.10 (t, J=7.3Hz, 2H), 2.65 (t, J=7.3Hz, 2H).
Anal. Calcd. for C28H22Cl2N2O2S•0.30 H2O C, 63.83; H, 4.32; N, 5.32. Found C, 63.80; H, 4.25; N, 5.12. -
- To a stirring solution of 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-propionamide (7.1 mmol, 2.88 g) in 58 ml THF cooled in an ice bath was added the LDA (9.9 mmol, 5.0 ml of a 2M heptane/THF/ethyl-benzene soln) dropwise and the solution stirred for 5 min. To this was added N-phenyltrifluoro-methylsulfonimide (9.9 mmol, 3.54 g) and the reaction stirred in an ice bath for 1h. The reaction was diluted with 200 ml H2O and extracted with 2 x 100 ml EtOAc. The combined organics were dried with brine and Na2SO4 and evaporated under vacuum to a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.72-6.99 (m, 8H), 5.80 (d, J=4.9Hz, 1H), 4.44 (t, J=5.6Hz, 1H), 3.44 (s, 3H), 3.05 (t, J=7.6Hz, 2H), 2.61 (t, J=7.6Hz, 2H).
- To a stirring solution of 2-bromopropene (6.5 mmol, 0.78 g, 0.58 ml) in 8 ml THF cooled to -78°C was added tert-butyllithium (13.0 mmol, 7.6 ml of a 1.7M pentane solution) dropwise. This was stirred 10 min, trimethyl borate (8.45 mmol, 0.88 g, 0.96 ml) was added and the reaction allowed to warm to rt. Concentration of this solution was calculated to be 0.41M.
- To a stirring solution of trifluoromethane sulfonic acid 3-[3-(2,4-dichlorophenyl)-propionylamino]-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl ester (1.3 mmol, 0.70 g) in 25 ml DME was added the Na2CO3 (2.6 mmol, 1.3 ml of a 2M aqueous solution), Pd[PPh3]4 (0.13 mmol,0.15 ), and LiCl (3.9 mmol, 0.16 g). To this was added 9.6 ml of the above boronate solution and the reaction heated to reflux for 2h. The reaction was cooled to rt, diluted with 200 ml saturated NaHCO3 and extracted with 2x100 ml EtOAc. The combined organic layers were dried with Na2SO4 and evaporated under vacuum. The residue was chromatographed over silica, eluting with 25% EtOAc:Hex. Collected pure fractions, evaporated under vacuum, crystallized from Et2O to give 160 mg of a white solid. mp 159-161°C: 1H NMR (300 MHz, CDCl3) δ 7.51-6.94 (m, 8H), 5.60 (d, J=5.4Hz, 1H), 5.17 (s, 1H), 5.00 (s, 1H), 4.51 (t, J=5.9Hz, 1H), 3.42 (s, 3H), 3.06 (t, J=7.3Hz, 2H), 2.60 (t, J=7.3Hz, 2H).
Anal. Calcd. for C23H22Cl2N202•0.25 H2O C, 63.68; H, 5.23; N, 6.46. Found C, 63.65; H, 5.03; N, 6.34. -
- To a stirring solution of 3-(2,4-Dichloro-phenyl)-N-(1-methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-propionamide (7.1 mmol, 2.88 g) in 58 ml THF cooled in an ice bath was added the LDA (9.9 mmol, 5.0 ml of a 2M heptane/THF/-ethylbenzene soln) dropwise and the solution stirred for 5 min. To this was added N-phenyltrifluoromethylsulfonimide (9.9 mmol, 3.54 g) and the reaction stirred in an ice bath for 1h. The reaction was diluted with 200 ml H2O and extracted with 2x100 ml EtOAc. The combined organics were dried with brine and Na2SO4 and evaporated under vacuum to a pale yellow solid. 1H NMR (300 MHz, CDC13) δ 7.72-6.99 (m, 8H), 5.80 (d, J=4.9Hz, 1H), 4.44 (t, J=5.6Hz, 1H), 3.44 (s, 3H), 3.05 (t, J=7.6Hz, 2H), 2.61 (t, J=7.6Hz, 2H).
- To a stirring solution of furan (2.8 mmol, 0.20 ml) in 2.0 ml THF cooled to -78°C was added butyllithium (3.64 mmol, 1.46 ml of a 2.5M hexane solution) dropwise and the reaction stirred for 10 min. Trimethyl borate (3.64 mmol, 0.37 g, 0.41 ml) was then added and the reaction allowed to warm to rt. The solution was calculated to be 0.7M.
- To a stirring solution of trifluoromethane sulfonic acid 3[3-(2,4-dichlorophenyl)-propionylamino]-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl ester (0.56 mmol, 0.3 g) in 10.5 ml DME was added the Na2CO3 (1.12 mmol, 0.56 ml of a 2M aqueous solution), Pd[PPh3]4 (0.28 mmol, 64.7 mg), and LiCl (1.68 mmol, 71.2 mg). The above boronate solution (1.4 mmol, 2.0 ml) was then added and the reaction heated to reflux for 2h. The reation was allowed to cool to rt, diluted with 100 ml H2O, and extracted with 2x5O ml EtOAc. The combined organics were dried with brine, Na2SO4 and evaporated under vacuum. The residue was chromatographed over silica, eluting with 25% to 50% EtOAc:Hex. Collected pure fractions, evaporated under vacuum, crystallized from Et2O to give 68.0 mg of a light beige solid. mp 120-124°C 1HNMR. (300 MHz, CDC13) δ 7.68-7.18 (m, 8H), 7.00-6.97 (m, 1H), 6.43-6.40 (m, 1H), 6.3-6.30 (m, 1H), 6.04 (d, J=5.9Hz, 1H), 4.62 (t, J=6.1Hz, 1H), 3.43 (s, 1H), 3.08 (t, J=7.6Hz, 2H), 2.62 (t, J=7.6Hz, 2H).
Anal. Calcd. for C24H20Cl2N2O3•0.30 H2O C, 62.57; H, 4.51; N, 6.08. Found C, 62.59; H, 4.21; N, 6.20. -
- A solution of N-(1-methyl-2,5-dioxo-3,4-dihydro-1H-benzo[b]azepin-3-yl)-3-(2,4-dichlorophenyl)-propionamide (500 mg 1.2 mmole) and pyrrolidine (180 mg, 2.5 mmole) in methanol (50 mL) was treated with acetic acid (125 mg) and sodium cyanoborohydride (157 mg, 2.5 mmole) and stirred at room temperature for two days. The reaction was diluted with 200 ml saturated NaHCO3 and extracted with 3 x 100 ml EtOAc. The combined organic layers were dried with MgSO4 and evaporated at reduced pressure. The residue was chromatographed over silica, eluting with 2% MeOH chloroform to give two isomers. Each isomer was converted into the hydrochloride salt by treatment with excess ethanolic HCl.
Isomer A: 130 mg, mp 160-163°C, Anal. Calcd. for C24H27C12N3O2•0.20 H2O•0.2 IP A C, 56.07; H, 6.05; N, 7.98. Found C, 55.66; H, 5.99; N, 7.90. Isomer B: 111 mg, mp 250-252°C, Anal. Calcd for C24H27C12N3O2•0.25 H2O C, 57.49; H, 5.73; N, 8.38. Found C, 57.43; H, 5.70; N, 8.54. -
- To a stirring solution of of 3-tertbutyloxycarbonylamino-2,3,4,5-tetrahydro-2,5-dioxobenzo[b]azepine (1.6 g, 5.5 mole) in THF (50 mL) was added Lawesson's reagent (2,4-bis(4-methoxy-phenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) (1.6 g, 4.1 mmole). The reaction was warmed gently and stirred at 60°C for one hour. The reaction was cooled to room temperature and concentrated at reduced pressure. The residue was crystallized from methanol and the solid collected to give the product. 1.1 g 1H NMR (300 Mz, CDCl3) δ 9.52 (s, 1H), 7.83 (app, d, J=7 Hz, 1H), 7.59 (app, t, J=7Hz, 1H), 7.38 (app, t, J=7Hz, 1H), 7.03 (app d, J=7 Hz, 1H), 6.14 (d, J=5 Hz, 1H), 5.03 (m, 1H), 3.30 (d, J=3, 19 Hz, 1H), 3.02 (d, J=7, 19Hz, 1H), 1.44 (s, 9H).
- To a stirring solution of the thioamide from step A (3-tert-butyloxycarbonylamino-2,3,4,5-tetrahydro-2-thio-5-oxo-benzo[b]-azepine (612 mg, 2 mmole) was added (S)-2-aminopropanol (750 mg, 10 mmole), and mercury (II) chloride (541 mg, 2 mmole). The reaction was stirred at room temperature for 15 minutes, filtered and concentrated at reduced pressure. The residue was dissolved in ethyl acetate (200 mL) and washed with saturated sodium bicarbonate (100 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was then chromatographed on silica gel eluting with 1.5%-5% methanol/-chloroform to give 502 mg of the intermediate hydroxyethyl amidine. The material thus obtained was dissolved in methylene chloride (20 mL) and treated with methanesulfonyl chloride (165 mg, 1.44 mmole) and Hunig's base (204 mg, 1.58 mmole). The reaction was stirred at room temperature for 15 minutes and then poured into saturated sodium bicarbonate (100 mL). The aqueous mixture was extracted with ethyl acetate (3 X 100 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure. The residue was then chromatographed on silica gel eluting with 2% methanol/chloroform. The pure fractions were combined and concentrared at reduced pressure. The residue was crystallized from ethyl acetate to give the product. 115 mg, mp 178-181°C.
Anal. Calcd for C18H23N3O2 C, 65.63; H, 7.04; N, 12.76. Found C, 65.38; H, 7.04; N, 12.54. - A solution of 1,2-dihydro-2-methyl-4-(tertbutyloxy-carbonylamino)-4H-imidazo[1,2-a]-6-oxobenzazepine (760 mg, 2.3 mmole) ethyl acetate (100 was treated with excess HCl gas until all of the starting material had been consumed. The reaction was concentrated at reduced pressure and the material thus obtained was dissolved in DMF and treated with EDC (0.47 g, 2.76 mmole), HOBT (0.37 g, 2.76 mmole), 2,4-dichlorophenyl propionic acid (0.6 g, 2.76 mmole), and triethylamine (0.23 g, 2.3 mmole). The reaction was stirred at room temperature for 30 minutes and then poured into saturated sodium bicarbonate (400 mL). The aqueous mixture was extracted with ethyl acetate (3 X 100 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered and concentrated at reduced pressure. The residue was then chromatographed with 1.5% methanol/chloroform to give the product (590 mg) as a mixture of isomers. The isomers were separated by chromatography on silica eluting with ethyl acetate.
- Isomer A crystallized from ethylacetate/Hexane. Isomer B was converted into the hydrochloride salt and freeze dried.
Isomer A: mp 134-136°C, Anal. Calcd for C22H21C12N3O2 C, 62.25; H, 5.36; N, 9.39. Found C, 62.04; H, 5.51; N, 9.06. Isomer B: Anal Calcd for C22H21Cl2N3O2•HCl C, 53.60; H, 5.09; N, 8.53. Found C, 53.56; H, 4.98; N, 8.19. -
- To a stirnng solution of of 3-benzyloxycarbonylamino-2,3,4,5-tetrahydro-2-oxobenzo[b]azepine (3.04 g, 0.98 mmole) in THF (100 mL) was added Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) (3 g, 0.75 mmole). The reaction was wanned gently and stirred at 60°C for one hour. The reaction was cooled to room temperature and concentrated in vacuo. The residue was crystallized from methanol and the solid collected to give the product (2.3 g).
1H NMR (CDC13) δ 9.5 (s, 1 H), 7.40-7.20 (m, 9H), 6.15 (d, J=7 Hz), 5.05 (app s, 2 H), 4.45 (m, 1H), 2.95-2.6 (m, 3H), 2.13-2.00 (m, 1H). - To a stirring solution of the thioamide from step A (3-benzyloxycarbonyiamino-2,3,4,5-tetrahydro-2-thiobenzo[b]azepine (980 mg, 3 mmole) was added (S)-2-aminopropanol (1.12 g, 15 mmole), and mercury (II) chloride (950 mg, 3.5 mmole). The reaction was stirred at room temperature for 15 minutes, heated to 60°C for 1 hour, filtered and diluted with ethyl acetate (300 mL). The ethyl acetate solution was washed with saturated sodium bicarbonate (50 mL) and then brine (50 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was dissolved in methylene chloride (75 mL) and treated with methanesulfonyl chloride (445 mg, 3.84 mmole) and Hunig's base (956 mg, 7.4 mmole). The reaction was stirred at room temperature for 15 minutes, diluted with ethyl acetate (300 mL), and then poured into saturated sodium bicarbonate (200 mL). The layers were separated and the aqueous mixture was extracted with ethyl acetate (2 X 100 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure. The residue was then chromatographed on silica gel eluting with 2% - 3% methanol/chloroform. The residue was crystallized from ether to give the product. (850 mg) as a mixture of diastereomers. mp 140-142°C.
Anal. Calcd for C21H23N3O2 C, 71.81; H, 6.66; N, 11.96. Found C, 71.76; H, 6.63; N, 11.86. - Step C: 2-(S)-N-(1,2,5,6-tetrahydro-2-methyl-4H-imidazo[1,2-a]benzazepin-4-yl)-3-(2,4-dichlorophenyimpropimamide. A solution of 1,2-dihydro-2-methyl-4-(benzyloxycarbonylamino)-4H-imidazo[1,2-a]-benzazepine (458 mg, 1.31 mmole) in methylene chloride (4 mL) was treated with excess HBr in acetic acid (5 mL of 30% solution) until all of the starting material had been consumed. The reaction was diluted with ether (100 mL) and the solvent decanted. The solid was washed with three additional 50 mL portions of ether and the solid dried at reduced pressure. The material thus obtained was dissolved in DMF and treated with EDC (0.259 g, 1.35 mmole) HOBT (0.182 g, 1.35 mmole), and 2,4-dichlorophenyl propionic acid (0.296 g, 1.35 mmole). The reaction was stirred at room temperature for 90 minutes and then poured into saturated sodium bicarbonate (100 mL). The aqueous mixture was extracted with ethyl acetate (3 X 100 mL). The combined organics were dried over anhydrous magnesium sulfate, filtered, and concentrated at reduced pressure. The residue was then chromatographed on silica gel eluting with 2 % - 4% methanol/-chloroform to give the product (151 mg) as a mixture of isomers. The mixture was converted into the hydrochloride salt and freeze dried.
Anal. Calcd for C22H23Cl2N3O•1.8 H2O C, 54.45; H, 5.73; N, 8.66. Found C, 54.49; H, 5.54; N, 8.58.
Claims (7)
- A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1, 2 or 3 or a pharmaceutically acceptable salt or hydrate thereof.
- The pharmaceutical formulation of Claim 4 comprising in addition another antiarrhythmic agent or other cardiovascular agent.
- A use of a compound of Claims 1, 2 or 3 for the manufacture of a medicament to prevent or treat arrhythmia.
- The use of Claim 6 in which the medicament additionally comprises another antiarrhythmic agent or other cardiovascular agent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15634893A | 1993-11-22 | 1993-11-22 | |
US156348 | 1993-11-22 | ||
PCT/US1994/013413 WO1995014671A1 (en) | 1993-11-22 | 1994-11-21 | 3-acylaminobenzazepines |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0730581A1 EP0730581A1 (en) | 1996-09-11 |
EP0730581A4 EP0730581A4 (en) | 1997-02-05 |
EP0730581B1 true EP0730581B1 (en) | 2001-10-04 |
Family
ID=22559195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95901954A Expired - Lifetime EP0730581B1 (en) | 1993-11-22 | 1994-11-21 | 3-acylaminobenzazepines |
Country Status (12)
Country | Link |
---|---|
US (1) | US5696111A (en) |
EP (1) | EP0730581B1 (en) |
JP (1) | JPH09505597A (en) |
AT (1) | ATE206402T1 (en) |
AU (1) | AU681924B2 (en) |
CA (1) | CA2176019A1 (en) |
DE (1) | DE69428546T2 (en) |
DK (1) | DK0730581T3 (en) |
ES (1) | ES2162907T3 (en) |
GR (1) | GR3036814T3 (en) |
PT (1) | PT730581E (en) |
WO (1) | WO1995014671A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0703222A1 (en) * | 1993-05-13 | 1996-03-27 | Yoshitomi Pharmaceutical Industries, Ltd. | 3-aminoazepine compound and pharmaceutical use thereof |
EP0785925A1 (en) * | 1994-10-04 | 1997-07-30 | Pfizer Inc. | Processes and intermediates for preparing 3-amino-benzo(b)azepinones |
US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6683075B1 (en) | 1996-12-23 | 2004-01-27 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use |
US5965734A (en) * | 1997-01-31 | 1999-10-12 | Celgene Corporation | Processes and intermediates for preparing 2-substituted piperidine stereoisomers |
US6958330B1 (en) | 1998-06-22 | 2005-10-25 | Elan Pharmaceuticals, Inc. | Polycyclic α-amino-ε-caprolactams and related compounds |
US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6774125B2 (en) | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
ATE327230T1 (en) | 2000-01-20 | 2006-06-15 | Eisai Co Ltd | PIPERIDINE COMPOUNDS AND MEDICATIONS CONTAINING SAME |
EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
DK1889198T3 (en) | 2005-04-28 | 2015-02-09 | Proteus Digital Health Inc | Pharma-informatics system |
WO2008036682A2 (en) | 2006-09-18 | 2008-03-27 | Raptor Pharmaceutical Inc. | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
DK2398500T3 (en) | 2009-02-20 | 2019-05-13 | 2 Bbb Medicines B V | GLUTATHION-BASED PHARMACEUTICAL DELIVERY SYSTEM |
IL255113B (en) | 2009-05-06 | 2022-09-01 | Laboratory Skin Care Inc | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
AR079170A1 (en) * | 2009-12-10 | 2011-12-28 | Lilly Co Eli | COMPOSITE OF CICLOPROPIL-BENZAMIDA-IMIDAZO-BENZAZEPINA INHIBITOR OF DIACIL-GLICEROL ACILTRANSFERASA, SALT OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE A USEFUL MEDICATION FOR THE TREATMENT OF INTEREST OR COMPENSATION |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
EP3978492A4 (en) * | 2019-05-31 | 2023-06-28 | Medshine Discovery Inc. | Bicyclic compound as rip-1 kinase inhibitor and application thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT75373B (en) * | 1981-08-12 | 1986-06-18 | Agripat Sa | Process for the preparation of tinted contact lenses |
DE3134672A1 (en) * | 1981-09-02 | 1983-03-17 | Boehringer Ingelheim KG, 6507 Ingelheim | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE |
US4473575A (en) * | 1982-07-19 | 1984-09-25 | Ciba-Geigy Corporation | 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids |
DE3373469D1 (en) * | 1982-09-30 | 1987-10-15 | Merck & Co Inc | 1-n-alkylcarboxy-benzofused lactams useful as antihypertensive agents |
DK151808C (en) * | 1982-11-16 | 1988-06-20 | Ferrosan As | ANALOGY PROCEDURE FOR THE PREPARATION OF OXADIAZOLYLIMIDAZO-OE1,4AA-BENZODIAZEPINE DERIVATIVES |
US4470988A (en) * | 1983-02-10 | 1984-09-11 | Ciba-Geigy Corporation | Benzazocinone and benzazoninone derivatives, and their pharmaceutical use |
US4537885A (en) * | 1983-02-10 | 1985-08-27 | Ciba Geigy Corporation | Certain benzazocinone and benzazoninone derivatives |
IL74070A (en) * | 1984-01-19 | 1988-12-30 | Hoffmann La Roche | Imidazodiazepine derivatives,their manufacture and pharmaceutical compositions containing them |
US4600534A (en) * | 1984-02-06 | 1986-07-15 | Ciba-Geigy Corporation | Process and intermediates for manufacture of 3-(5-amino-1-carboxypentylamino)-tetrahydro-1-benzazepin-2-one-1-acetic acid |
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
US4692522A (en) * | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
DE3752308T2 (en) * | 1986-10-13 | 2000-08-24 | Sumitomo Dow Ltd | Thermoplastic resin composition containing an organometallic dye |
US4847248A (en) * | 1986-12-23 | 1989-07-11 | Merck & Co., Inc. | 1,4-Benzodiazepines with 5- and 6-membered heterocyclic rings and their use as cholecystokinins and gastrin antagonists |
EP0322779A3 (en) * | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
IT215722Z2 (en) * | 1989-02-21 | 1990-10-26 | Giancarlo De Giacomi | GLASSES WITH REARVIEW MIRRORS ADJUSTABLE IN ALL DIRECTIONS. |
US5206234A (en) * | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
DE4125457A1 (en) * | 1991-08-01 | 1993-02-04 | Bayer Ag | METHOD FOR PRODUCING N-SUBSTITUTED LACTAMES |
WO1993008175A1 (en) * | 1991-10-24 | 1993-04-29 | Glaxo Group Limited | Benzodiazepine derivatives as antagonists of gastrin and/or cholecystokinin |
TW213901B (en) * | 1992-01-27 | 1993-10-01 | Pfizer | |
IT1254558B (en) * | 1992-03-26 | 1995-09-25 | Mini Ricerca Scient Tecnolog | COMPOUNDS BASED ON 3,4-DIARYL (5H) -FURAN-2-ONE WITH FUNGICIDE ACTIVITY 3 |
EP0703222A1 (en) * | 1993-05-13 | 1996-03-27 | Yoshitomi Pharmaceutical Industries, Ltd. | 3-aminoazepine compound and pharmaceutical use thereof |
JPH09314058A (en) * | 1996-05-31 | 1997-12-09 | Toshiba Eng Co Ltd | Foreign matter capturing device |
-
1994
- 1994-11-21 PT PT95901954T patent/PT730581E/en unknown
- 1994-11-21 WO PCT/US1994/013413 patent/WO1995014671A1/en active IP Right Grant
- 1994-11-21 AU AU11004/95A patent/AU681924B2/en not_active Ceased
- 1994-11-21 EP EP95901954A patent/EP0730581B1/en not_active Expired - Lifetime
- 1994-11-21 JP JP7515168A patent/JPH09505597A/en not_active Ceased
- 1994-11-21 US US08/646,368 patent/US5696111A/en not_active Expired - Fee Related
- 1994-11-21 DK DK95901954T patent/DK0730581T3/en active
- 1994-11-21 ES ES95901954T patent/ES2162907T3/en not_active Expired - Lifetime
- 1994-11-21 DE DE69428546T patent/DE69428546T2/en not_active Expired - Fee Related
- 1994-11-21 AT AT95901954T patent/ATE206402T1/en not_active IP Right Cessation
- 1994-11-21 CA CA002176019A patent/CA2176019A1/en not_active Abandoned
-
2001
- 2001-10-05 GR GR20010401427T patent/GR3036814T3/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GR3036814T3 (en) | 2002-01-31 |
WO1995014671A1 (en) | 1995-06-01 |
DK0730581T3 (en) | 2001-11-26 |
EP0730581A4 (en) | 1997-02-05 |
ES2162907T3 (en) | 2002-01-16 |
PT730581E (en) | 2002-02-28 |
AU1100495A (en) | 1995-06-13 |
EP0730581A1 (en) | 1996-09-11 |
DE69428546D1 (en) | 2001-11-08 |
CA2176019A1 (en) | 1995-06-01 |
AU681924B2 (en) | 1997-09-11 |
ATE206402T1 (en) | 2001-10-15 |
US5696111A (en) | 1997-12-09 |
DE69428546T2 (en) | 2002-04-11 |
JPH09505597A (en) | 1997-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0730581B1 (en) | 3-acylaminobenzazepines | |
AU695159B2 (en) | Antiarrhythmic benzodiazepines | |
EP0830350B1 (en) | n-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1h-benzo[b][1,5]diazepin-3-yl)-acetamides | |
AU686715B2 (en) | Tricyclic benzodiazepinyl amide derivatives as amtiarrhythmics | |
EP1392663A2 (en) | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | |
EP0832075B1 (en) | n-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3y l)-3-amides | |
AU722110B2 (en) | Pharmaceutical preparation | |
AU682562B2 (en) | 3-acylaminobenzodiazepines | |
WO1997048686A1 (en) | Novel n-1 alkyl-2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amides | |
US6214823B1 (en) | Benzodiazepine derivatives as antiarrhythmic agents | |
AU1082799A (en) | Novel benzodiazepine derivatives as antiarrhythmic agents | |
NZ328938A (en) | Arrhythmia treatment using benzodiazepine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960624 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19961220 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19990215 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
REF | Corresponds to: |
Ref document number: 206402 Country of ref document: AT Date of ref document: 20011015 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69428546 Country of ref document: DE Date of ref document: 20011108 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2162907 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20010401427 Country of ref document: GR |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20011122 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20020916 Year of fee payment: 9 |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20020925 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20020927 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20021002 Year of fee payment: 9 Ref country code: AT Payment date: 20021002 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20021011 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20021022 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20021023 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20021024 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20021106 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20021119 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20021127 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20021213 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20021223 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031121 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031121 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031121 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031122 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031130 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031201 |
|
BERE | Be: lapsed |
Owner name: *MERCK & CO. INC. Effective date: 20031130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040602 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040603 |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20031121 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040730 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20040601 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20040531 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20031122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20051121 |